Indaptus Therapeutics, Inc. - 8-K Filing

Indaptus Therapeutics reports Q3 2026 results with $24M private placement and significant reductions in R&D and G&A expenses. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $INDP

Read the full article at SEC EDGAR

More Regulatory news